Targeting CD30 in Hodgkin Lymphoma

Video

For High-Definition, Click

According to John Sweetenham, MD, it has been well known for a number of years that there is cell communication within the Hodgkin lymphoma lymph node that is important to cell survival, particularly between Reed-Sternberg cells and inflammatory background infiltrate. Now, new data suggest that Reed-Sternberg cells form a network of cells that are linked by CD30-bearing protrusions. Cross talk mechnisms may exist between the Reed-Sternberg cells and the protrusions that express CD30, making CD30 an even better target for therapy, Sweetenham suggests.

Until the approval of the antibody-drug conjugate brentuximab vedotin, CD30 remained an elusive target. Brentuximab vedotin binds to CD30 and internalizes, causing the release of the anti-tubulin cytotoxic MMAE within the cancer cell. MMAE works to disrupts the microtubule network, causing cell cycle arrest and apoptosis. Targeting tubulin helps break down the protrusions and membrane-bound vesicles, resulting in a loss of cell communication and reduced survival of Reed-Sternberg cells.

Related Videos
Marc J. Braunstein, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Jorge J. Castillo, MD,
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Alessandra Ferrajoli, MD
Dipti Patel-Donnelly, MD, Johns Hopkins
Jasmin M. Zain, MD
Andrew Ip, MD